Precision medicine can advance if we find new ways to select therapies that will provide a patient with clinical benefit. Biodesix® provides end-to-end diagnostic solutions, using artificial intelligence for blood-based biomarker discovery. From test design to commercialization, we collaborate with our biopharma partners to help identify patients that will benefit from their drugs in clinical development.
Biodesix offers novel, blood-based biomarker discovery solutions for our biopharma partners. To address the increasing complexity of new drug mechanisms and disease, Biodesix designs and develops robust, multi-omic tests using modern machine learning. Our technology platforms currently include Droplet Digital™ PCR (ddPCR), next generation sequencing (NGS), MALDI-ToF mass spectrometry, and liquid chromatography mass spectrometry (LC-MS).
Biomarker Evaluation Process in Partnership with Biodesix
Design, develop, and deliver the basic building block for a test to our partner.
Prototype Test Development
Optimize the prototype test based on our partner’s needs.
Companion Proof of Concept
Confirm the test performance on relevant clinical patient samples.